Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price objective of $12.00 for the company, according to Zacks. Zacks has also given Eleven Biotherapeutics an industry rank of 92 out of 265 based on the ratings given to its competitors.
Eleven Biotherapeutics (NASDAQ:EBIO) opened at 2.80 on Thursday. Eleven Biotherapeutics has a 52 week low of $0.25 and a 52 week high of $5.97. The stock’s 50 day moving average is $4.23 and its 200 day moving average is $2.31. The stock’s market cap is $43.10 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter. Eleven Biotherapeutics had a negative return on equity of 207.40% and a negative net margin of 2,995.34%. Analysts predict that Eleven Biotherapeutics will post ($1.75) EPS for the current year.
In related news, major shareholder Ventures Fund Iv L.P Flagship sold 9,700 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $3.31, for a total transaction of $32,107.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Abbie Celniker sold 10,031 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $3.00, for a total transaction of $30,093.00. Following the transaction, the director now owns 409,915 shares of the company’s stock, valued at approximately $1,229,745. The disclosure for this sale can be found here. 28.70% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of EBIO. Bank of New York Mellon Corp raised its position in Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 7,846 shares during the period. Boxer Capital LLC purchased a new position in Eleven Biotherapeutics during the second quarter valued at approximately $1,670,000. Sabby Management LLC raised its position in Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 1,019,943 shares during the period. Flagship Ventures Fund IV General Partner LLC purchased a new position in Eleven Biotherapeutics during the second quarter valued at approximately $2,464,000. Finally, Flagship Ventures Fund IV L.P. purchased a new position in Eleven Biotherapeutics during the first quarter valued at approximately $469,000. Hedge funds and other institutional investors own 34.32% of the company’s stock.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.